PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
A FCA-regulated property marketplace that aims to be the central hub for buyers, sellers, renters, landlords and agents to access property listings. The House Shop lists over 3 million properties on their platform and in January 2018 alone, they achieved over 800k site visits. The company offers users the ability to perform private and professional transactions through the website, whilst acquiring knowledge and insight on the property market.
Over the last 3 years, The House Shop has seen their customer traffic increase by 8 times and managed to achieve landlord acquisitions at a low cost. The company has also been featured in major publications and has partnered with large firms such as HM Land Registry, Experian and National Landlords Association.
days to go:
Expired
investment:
£273,580
Authenticating artwork by using DNA tags to produce certificates as a solution to forgery and fraud. Tagsmart has almost 250 artists with over 11,000 tags issued across more than 23,000 pieces of artwork. Revenue is generated via commissions with retailers where the artwork is sold, rather than from the artist. Funding will be aimed at R&D to continuously improve the security and to take the brand worldwide due to interest and demand from overseas.
days to go:
Expired
investment:
£503,925
Receive an affordable massage at home and on-demand by easily booking straight from an app. Since the start of year, Urban Massage has delivered more than 114,000 massages and received a 4.85/5 or above rating for the level of treatment provided to their customers. The company has successfully launched in Birmingham, Manchester and Paris with an Annualised Run Rate (ARR) of 3,300% from June 2014 and in June 2018, an ARR of £10.4m.
days to go:
Expired
investment:
£3,491,730
The Gut Stuff is a proactive advocate for gut health, educating a substantial community and offering an innovative app in BETA that aims to bridge gaps in the gut health market. With a strong presence in physical products, workplace education, and media, they're positioned to redefine the gut health category and leverage diversified revenue streams for growth during their expansion into the digital realm.
days to go:
Expired
investment:
£321,662
Ortharize is a business travel platform that enables companies to cut their travel bills by rewarding their employees for spending less on flights, hotels and trains. With a proven business model, the company is confident that their innovative incentives platform coupled with competitive customer pricing will lead to rapid growth. They are in talks with Expenses Software Company to rollout to 1000+ customers. Moreover, through its partnership with Travel & Transport, Ortharize also has access to global airline and hotel inventory with pre-negotiated discounts and commission from launch. The company is planning to exit within 5 years and expect this to be through a trade sale.
days to go:
Expired
investment:
£435,360
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.
days to go:
Expired
investment:
£290,278
